UnitedHealth's Rebound: Hidden Strength or Hiding Weakness?
Recently, UnitedHealth Group (UNH, Financial) has been the subject of many headlines because of DOJ probes, kickback accusations in nursing homes, and a shocking departure of its CEO. In addition, the value of its shares has dropped by almost 50%. Yet, underneath the news, the business is still strong. Health insurance remains important and strong throughout economic downturns and doesn't react to changes in global trade. In the aftermath, a clear development can be noticed as Stephen Hemsley was appointed CEO again and bought a large amount of stock which fueled a quick increase in share prices.
Warning! GuruFocus has detected 4 Warning Sign with UNH.
This is real conviction. UnitedHealth is focusing more on Medicaid-managed care, widening value-based care with Optum, and looking into growing its business in dual-eligible and long-term care. The company's financials confirm the trend since earnings have quadrupled in ten years, cash flow is strong, and insiders are buying in.
In short, UnitedHealth is using the uncertainty to its advantage. Long-term investors may find the current price as an attractive chance to enter a company that has shown lasting and solid growth.
UnitedHealth Group is the biggest health insurer in the United States and ranks highly internationally in healthcare. Its two key segments, UnitedHealthcare and Optum, give people health benefits, pharmacy services, data analysis, and healthcare. More than 150 million people are helped by this company, which is continuing to expand by combining operations and offering value-based care. The company provides insurance through commercial, Medicare, and Medicaid markets, and Optum sparks new ideas in care coordination and pharmaceutical services.
UnitedHealth is smartly diversified. The company is doing well due to managed care growth, making money from healthcare improvements, and strategically serving top segments thanks to Optum doing the main work.
Medicaid managed care expansion capturing state-level shifts: The move of Medicaid recipients from fee-for-service to managed care can bring huge benefits to UnitedHealth. According to industry statistics, UNH and four other large insurers cover over 50% of people in Medicaid-managed care across the nation. So, when several hundred thousand to millions switch plans, it has a huge effect on the company's finances. Since monthly premiums for complex patients in these states are $600$800, New York, Pennsylvania, and Michigan could add hundreds of millions of dollars to their annual premium earnings. Because of its connections with states, UNH is in a good position to win a major share of this revenue.
Value-based care & optum scale turning outcomes into profit: Optum, which drives UNH's value-based approach, recorded $253 billion in revenue in 2024, which was 12% higher than the previous year, and $16.7 billion in operating income. Currently, Optum Health works with close to 4.7 million people in value-based contracts and plans to add another 650k in 2025. Focus on patient care and cost savings are the main aims of these models, and UNH supports this. When Optum grows its care coordination and home services, shared-savings revenue plays a bigger role, already bringing in hundreds of millions and capable of much more.
High-Value segments target the dual-eligible and long-term care markets: Instead of raising its volume, UNH is focusing on high-paying customer groups, such as those with both Medicare and Medicaid and patients needing long-term care. Dual-eligibles may receive $2,500 monthly, which means each person will get $30,000 annually. Currently, UNH serves about 500k people, but if it could capture just 2 million of the national enrollments, it could earn $45 billion in annual premiums.
Vertical integration with optum: Thanks to Optum, UNH has all its services combined, including pharmacy (over 1.62 billion scripts were handled by OptumRx in 2024), care delivery, data analysis, and provider management. Because of this integration, UNH is ahead in long-term care, managing care effectively, reducing expenses, and boosting results, which other organizations don't have.
Overall, UnitedHealth is a leader that is making steady earnings now and is prepared to capture the future of healthcare and population wellness.
Now, let's investigate the financial side of UnitedHealth Group. The company had good first-quarter earnings, but it sent a cautious message for the coming months. UnitedHealth Group's quarterly revenue of $109.6 billion was $10 billion higher than the same period last year, showing how much both UnitedHealthcare and Optum are growing. While adjusted EPS of $7.20 surpassed $6.91 from the earlier period, the company adjusted its full-year forecast down to expect adjusted EPS of $26.00 to $26.50.
So, what leads to this change of tone? While UnitedHealthcare welcomed 780,000 new members, increased use of health services in Medicare Advantage by its customers caused the company's medical costs to increase above expectations. Because more people needed outpatient and physician care, the medical care ratio rose to 84.8%. For healthcare delivery, this is not necessarily an issue, yet it can still hurt business if prices fall short.
Meanwhile, Optum Health experienced challenges with a more diverse member group and reduced payments due to less involvement among members in 2024. Even so, Optum achieved a $63.9 billion revenue thanks to its Rx division, which filled 408 million adjusted scripts. UNH is also operating efficiently, with its operating cost ratio now 12.4%, free cash flow at $5.5 billion, and a high 26.8% return on equity. The company also gave $5 billion back to its shareholders.
All in all, UNH's basics are solid, but it has to deal with some short-term problems first.
UnitedHealth Group has consistently improved its earnings over the years. In the year 2015, diluted earnings per share was only $6.01. Looking at the trailing twelve months, the number has reached $23.88. Over the past decade, the amount has almost quadrupled.
It is even more impressive that the growth has been steady over the years. For many years, UnitedHealth kept increasing its profits, demonstrating the power of its varied businesses and strict management. The only major drop in EPS happened in 2024, with the figure reaching $15.51. Although this was an unusual dip in the company's history, it is on track for a solid recovery in 2025, and first-quarter adjusted EPS was $7.20.
Looking into the future, analysts believe the trend will not stop. Even though 2025 is, in some ways, a year of recovery with a projected EPS of $22.59, the company's growth kicks in afterward. By 2026, analysts predict EPS will increase to $26.40, and then keep growing at double-digit rates, aiming for $45.83 by 2030.
Source: Author generated based on historical data
All in all, despite some occasional setbacks, UnitedHealth's future growth is steady, so patient investors are still in a position to be rewarded.
The increase in EPS matches the upward trend in revenue per share. It highlights the company's steady growth and increased success. In the year 2015, the company's revenue per share was $162.47. Now, that figure is $443.16 TTM. That's a 170% jump in ten years, which clearly shows the company is making better use of its growth to help shareholders.
What's most promising is that this growth keeps happening consistently. Revenue per share has increased year after year and stayed strong through different economic conditions and impacts on the industry. It is a result of the company attracting more members and expanding its main businesses, UnitedHealthcare and Optum.
Once more, this trend keeps happening in the future. Revenue forecasts keep going up from $449.81 billion in 2025 to more than $591 billion by 2030. Minor changes in growth do not stop the company from expanding and creating more value for its shareholders.
Source: Author generated based on historical data
UnitedHealth Group's free cash flow per share is a reliable sign of how well the company is financially and operationally. The amount of free cash flow per share in 2015 was $8.46. Afterward, the company increased this number, reaching $26.82 for the TTM, which is more than three times higher than its value a decade back.
What stands out about this growth is that it follows closely in line with the company's earnings trajectory. Therefore, we see that UnitedHealth's profits are being turned into cash that can be used to strengthen the business, cut debt, or be given back to its shareholders. Being that efficient is not common in an industry that relies heavily on capital like healthcare.
UnitedHealth Group gives investors a good dividend since the dividend yield is 2.92% and the payout ratio is only 30%, which suggests that dividends could increase in the future. It's worth noting that over the past 5 years, the company has seen a 14.6% growth in its dividend, which tops inflation and profits long-term investors. Through ten years of constant raises, the yield on cost increases to 15.38%. Although UNH is offering a high yield now, low buybacks mean most capital is shared through dividends.
UnitedHealth Group looks deeply undervalued right now. According to GuruFocus, the stock is trading about half its worth, as the fair value is $633.16 but it is currently trading at $303.22. There is a massive disconnect here, and it's very unusual for a company as stable as UNH to deviate so much from its fair value estimate.
Valuation multiples are also telling the same story. The forward P/E of this stock is 13.42, which is much lower than the average of 17.66, giving a discount of 23.98%. The company's forward EV/EBITDA of 9.61 is better than the sector's ratio of 11.79. On a price-to-sales ratio, UNH is trading at 0.61 times its projected sales, while the healthcare industry is pricing in at 3.43xa discount of 82%.
All in all, UNH gives you both quality and value. Almost all of the valuation measures suggest that the company is undervalued in terms of its earnings, sales, and cash flow. Even though the stock is built on solid foundations and pays out more in dividends each year, it still trades at a lower price than its competitors. As a result, long-term investors can take advantage of acquiring a leader in healthcare at a much lower price than its actual value.
When measured against companies like Humana (HUM, Financial) and HealthEquity (HQY, Financial), UnitedHealth Group is still a good buy. Because its forward P/E is lower than HUM's 14.1 times and much lower than HQY's 30 times, it attracts those who want to invest for growth as well as value. Considering price-to-sales, UNH trades at 0.68 times, making it more valuable than HQY's 7.8 while being slightly higher than HUM's very low 0.23. On the EV/EBITDA ratio, UNH stands at 9.6x forward, quite similar to HUM's 9.2x and much less than HQY's 19.2x.
All in all, UNH is well-balanced by giving investors scale, profits, dividend growth, and a reasonably attractive price. HUM also does well in various areas, especially when it comes to managing expenses and the way the company works. But in the long run, investors admire UNH for its consistent results and potential to increase.
Source: Author generated based on data
Going forward, I feel UnitedHealth Group (NYSE:UNH) is well-positioned to achieve a price target of $395$410 in the next year and possibly surpass $525$550 by 2027. Despite the stock's recent volatility, the numbers, the company's health, and the outlook seem to fit together nicely.
Let's begin our discussion with the short term. Despite many years of increasing earnings and a high rate of cash conversion, UNH is only valued at 13.4 times its future earnings when the stock is trading at $303. Healthcare companies, on the other hand, have a forward P/E of about 17.6, and UNH has generally had a forward P/E between 18x and 20x during calm times. If UNH is valued at just 17 times the expected FY2025 EPS of $22.59, the price would come to $384. At 18x, If stability comes back and the new leaders reassure everyone, the stock could increase to $406.
The story gets even better as you look further into the future. Analysts are predicting that EPS will rise to $45.83 by 2030, meaning it will be about double the current earnings in just five years. Multiply the earnings by 15, and the share price comes out to $687. But, let's narrow our focus to conservatism, and for 2027, the predicted EPS is about $34.50. At this multiple of 15x, the price comes out to $517if the market recovers, shares could climb to $550 or more due to the 16x or 17x rating. If the DOJ investigation ends well and Hemsley's efforts to cut costs are successful, the company should do well over the next few quarters.
We are not just discussing theory here. Since 2015, UNH's free cash flow per share has more than tripled, its revenue per share has nearly tripled too, and it still has some of the top dividend growth rates in healthcare. Such consistency, size, and under-valuation are hard to find in one company.
Let's look at how Wall Street views this area. Looking at the chart, analysts foresee that the price of Apple shares might rise by 26.2% to $382.80 in the next 12 months. It is estimated that the cost can fall anywhere from $270 to $677.
To conclude, although there may be short-term ups and downs, it looks like disciplined, patient investors will find more favorable long-term conditions.
When Andrew Witty suddenly left his CEO post in May because of profit problems and dropped 2025 guidance, UNH shares fell over 12% to their lowest point in five years and wiped out more than $250 billion in market value.
As a consequence, the board brought back former CEO Stephen Hemsley (who headed the company from 2006 to 2017). Within only a few days, Hemsley made a big step by buying nearly 86,700 shares worth about $25 million for $288.60 per share. Hemsley, together with the CFO and several directors, voted to keep the company's value high, and shares rose by about 8% the following trading day.
What does it imply? It is clear that the management views the falling share price of UNH as a good time to purchase. The fact that Hemsley has invested his money shows how much he believes in the company after all it has achieved. Yet, this is not a case of blind faith: the company is dealing with an ongoing investigation, higher medical costs in Medicare Advantage, and a cyberattack it suffered recently.
From a strategic point of view, all this buying in UNH suggests that the company's leaders believe the worst has passed and risks for the stock are low.
The guru trading chart has an interesting narrative. Although UnitedHealth's stock has gone down recently, gurus have been buying it more frequently. Many green bars are appearing, both early in 2024 and again later in 2025, showing that some informed investors are looking at the dip as an opportunity to buy instead of a warning sign.
This trend can be seen in the investor's stock portfolio. Vanguard is still the biggest shareholder, but it slightly reduced its holdings. I'm also paying attention to Ken Fisher (Trades, Portfolio) , who bought much more, a solid 52%, and Jeremy Grantham (Trades, Portfolio) , who increased his holding by over 7%. Though there is selling and shares are reduced as well, institutions tend to be cautiously upbeat.
Even though UnitedHealth's future looks bright, investors should still pay attention to the risks in the near term. The DOJ is currently investigating the business for possible Medicare Advantage fraud, such as upcoding and billing errors, which is a very serious matter that could result in being fined or charged in court. At the same moment, Washington is paying more attention to supervision. Should reforms reduce the inflation of risk scores or Medicare allowance for nurse practitioners, it could affect the profitability of Medicare Advantage.
Q1 faced some issues because the higher use of medical services caused the medical loss ratio to increase to around 85%, and Optum is still learning to handle CMS's updated risk model. Because of these pressures, there could be more budget reductions for guidance.
However, the bad news appears to be mostly factored into share prices. For careful investors who believe the company will survive, this could present an opportunity to buy long-term.
The headlines can be very tempting, but stepping back, it appears that UnitedHealth is still a powerhouse lurking in plain sight. It is the same old stuff but with a different sentiment. The long-term story is still in place with the reinstatement of Stephen Hemsley, a recent insider purchase, and a long history of expertise in Medicaid-managed care and the Optum platform in value-based care.
Most of that bad news, including the increases in care costs, and regulatory noise, appears to be reflected in price. Sentiment can change at any minute as long as we hear a resolution to the DOJ investigation, a slowdown in the trend of rising Medicare costs, or upbeat guidance in coming quarters. Any of those may be the spark.
In the meantime, the stock is currently trading at one of the most attractive valuations it has seen in years, and the set-up is of the sort long-term investors tend to reflect back on with gratitude. If you are waiting to have a clear picture, you may miss the opportunity. However, to the patient and longer-term investors, this may be one of those times when interceding in soreness results in actual payoff.
In other words, this just might be a smart time to lean in and buy the stock.
This article first appeared on GuruFocus.
Effettua l'accesso per consultare il tuo portafoglio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
SoftBank founder proposes $1trn AI and robotics hub in US
SoftBank Group founder Masayoshi Son is pursuing a plan to establish a $1trn industrial complex in Arizona, the US, to create a major hub for AI and robotics manufacturing, reported Bloomberg. The Japanese investment firm has approached Taiwan Semiconductor Manufacturing (TSMC) to play a key role in the project, though the specifics of TSMC's potential involvement remain unclear. The proposed complex, dubbed 'Project Crystal Land,' envisions a high-tech manufacturing hub akin to China's Shenzhen, individuals familiar with the plan told the publication. The park could include production lines for AI-powered industrial robots, they said, though the discussions remain private. SoftBank has also engaged with Samsung Electronics executives to gauge interest, alongside a range of other technology companies, the report added. SoftBank officials have held discussions with US federal and state government officials, including US Secretary of Commerce Howard Lutnick, to explore potential tax incentives for companies investing in the industrial park. Son has compiled a list of SoftBank Vision Fund portfolio companies, such as robotics firm Agile Robots SE, that could establish production facilities at the site. The project's feasibility depends on support from the Trump administration and state authorities. While the envisioned cost could reach $1trn, as previously reported by the Nikkei, the actual scale will hinge on participation from major technology firms, Bloomberg's report said. If successful, Son has suggested the possibility of developing additional advanced industrial parks across the US. TSMC, which has already begun mass production at its first Arizona factory as part of a $165bn US investment, indicated that SoftBank's project does not impact its existing plans in Phoenix. Representatives from SoftBank, TSMC, and Samsung declined to comment, and the US Commerce Department did not immediately respond to Bloomberg's inquiries. In March 2025, SoftBank agreed to acquire Ampere Computing, a US-based semiconductor design company, for $6.5bn. As per the deal, Ampere Computing will be acquired by SBG through its subsidiary Silver Bands 6 (US) Corp. Ampere Computing is engaged in developing high-performance, energy-efficient processors tailored for cloud computing and AI workloads. The company currently employs approximately 1000 engineers. "SoftBank founder proposes $1trn AI and robotics hub in US" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
How to ask for a raise: 6 mistakes that can hurt your chances — and what to do instead
Only 13% of full-time employees requested a raise in 2023, but 66% of those who did received one, according to a May 2024 Federal Reserve survey. It goes to prove the old saying right: Ask, and you shall receive. Still, asking for a raise at work can be a stressful conversation for many employees. If you ask at the wrong time or in the wrong way, you could hurt your chances. From asking too soon to giving ultimatums, even minor missteps can work against you. In many ways, it's a skill of its own. Here are six mistakes to avoid, along with practical tips to approach salary discussions with confidence and increase your odds of success. Before asking for a raise, it's essential to establish a strong relationship with your manager. Otherwise, the conversation won't go far. 'Before giving a raise, I would want to know what my employee is doing and have a regular cadence where we're meeting consistently,' says Patrice Williams-Lindo, a career coach and manager of five. 'If it's the first time we're meeting, it's impractical to ask for a raise then and there. It's like asking someone to marry you on the first date,' she explains. Set up regular one-on-one meetings with your manager if you haven't already done so. Use that time to keep them updated on your progress, share your wins and make sure you're aligned on goals, including earning a salary increase. It will also give your manager a clear understanding of how you and your work contribute to the team. Do you work for a great organization? Nominate it as one of America's Top Workplaces. Even after you've established a relationship with your manager, avoid requesting a raise in an arbitrary one-on-one meeting, via email or during a casual conversation. Your manager should know the conversation is coming. 'It shouldn't be an ambush,' Williams-Lindo says. 'When you book the meeting, say, 'I'd like to talk about compensation and share the results I've driven,'' she advises. Schedule a dedicated meeting and clearly state its purpose. That way, your manager has time to prepare and come to the conversation with the right mindset. Timing can significantly impact whether your raise request is granted. If you're unsure when your company typically handles raises or promotions, bring it up during your one-on-ones, then use the intervening time to work toward that raise. 'If I'm setting myself up for mid-year, then I need to start at the beginning of the year — if not before — building that case,' Williams-Lindo says. Map out what you want to achieve for the year ahead and start gathering proof points early, so by the time you discuss a raise or promotion with your manager, your case will already be well established. Avoid asking for a raise out of fear or personal financial pressure. Instead, keep the focus on your performance and value. Williams-Lindo suggested saying something like, ''It's been X months — here's what I've done, the caliber of my work and the outcomes I've delivered. That's why I believe I'm qualified for X, Y or Z.' That gives off a different energy than, 'Hey, I don't know how I'm going to pay my rent, and I need a raise.'' Center the conversation on your professional achievements and value. Know what the market is paying for your role and what peers in similar roles (even at other organizations) are making. If you can demonstrate the gap, you're more likely to have a productive outcome. Giving an ultimatum when asking for a raise is a major mistake. Even if you do get the raise, this type of communication can antagonize your manager, damage your professional reputation and ultimately undermine your value. 'This might sound like, 'I need a raise, or I'm quitting.' I appreciate that bravado, but for me, it's a bit of a turn-off, because how did we get here?' Williams-Lindo says. Rehearse your talking points. Calm, professional conversations are far more effective than explosive ones. Be open to negotiation and prepared to compromise on the final amount. Even if you've thoroughly prepared and presented your case well, your raise request could still be denied. If you're told "not right now," ask your manager for specific feedback. There may be outside factors influencing the decision or specific goals you'll need to meet to be considered for a raise in the future. A good manager will explain the reason — whether it's because the company is facing a downturn or because there are performance gaps to work on — and then help you to fix them. Set up a follow-up time — in three to six months — to revisit the conversation. This will indicate that you are engaged and goal-oriented. If your manager is dismissive and doesn't provide clear, achievable paths to advancement, it may be time to reassess if this is still the right place for your growth. This article originally appeared on USA TODAY: how-to-ask-for-raise
Yahoo
an hour ago
- Yahoo
Public companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%
The considerable ownership by public companies in Gyre Therapeutics indicates that they collectively have a greater say in management and business strategy 71% of the company is held by a single shareholder (GNI Group Ltd.) Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. If you want to know who really controls Gyre Therapeutics, Inc. (NASDAQ:GYRE), then you'll have to look at the makeup of its share registry. With 71% stake, public companies possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Individual investors, on the other hand, account for 19% of the company's stockholders. In the chart below, we zoom in on the different ownership groups of Gyre Therapeutics. See our latest analysis for Gyre Therapeutics Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. Institutions have a very small stake in Gyre Therapeutics. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too. We note that hedge funds don't have a meaningful investment in Gyre Therapeutics. GNI Group Ltd. is currently the largest shareholder, with 71% of shares outstanding. This implies that they have majority interest control of the future of the company. Meanwhile, the second and third largest shareholders, hold 3.1% and 3.1%, of the shares outstanding, respectively. Songjiang Ma, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. We can see that insiders own shares in Gyre Therapeutics, Inc.. In their own names, insiders own US$53m worth of stock in the US$755m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. The general public, who are usually individual investors, hold a 19% stake in Gyre Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. It appears to us that public companies own 71% of Gyre Therapeutics. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership. It's always worth thinking about the different groups who own shares in a company. But to understand Gyre Therapeutics better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Gyre Therapeutics (of which 1 makes us a bit uncomfortable!) you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
